Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Driving Performance in Young Adults with ADHD (Amphetamine ER)
NCT04027361Phase 2Completed
- Sponsor
- Tris Pharma
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amphetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Tris Pharma. Started Oct 2019; status: completed.
02
Drugs
amphetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04027361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04027361.